Wijtske Annema1, Hendrik M Willemsen2, Jan Freark de Boer3, Arne Dikkers3, Markus van der Giet4, Wybe Nieuwland2, Anneke C Muller Kobold5, L Joost van Pelt5, Riemer H J A Slart6, Iwan C C van der Horst2, Robin P F Dullaart7, René A Tio8, Uwe J F Tietge9. 1. Department of Pediatrics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; Top Institute Food and Nutrition, Wageningen, The Netherlands. 2. Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 3. Department of Pediatrics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 4. Division of Nephrology and Endocrinology, Charité Campus Benjamin Franklin, Berlin, Germany. 5. Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 6. Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; Cardiovascular Imaging Group Groningen, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 7. Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 8. Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; Cardiovascular Imaging Group Groningen, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 9. Department of Pediatrics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; Top Institute Food and Nutrition, Wageningen, The Netherlands. Electronic address: u_tietge@yahoo.com.
Abstract
BACKGROUND: High-density lipoproteins (HDLs) protect against the development of atherosclerotic cardiovascular disease. HDL function represents an emerging concept in cardiovascular research. OBJECTIVE: This study investigated the association between HDL functionality and acute myocardial infarction (MI) independent of HDL-cholesterol plasma levels. METHODS: Participants (non-ST-segment elevation MI, non-STEMI, n = 41; STEMI, n = 37; non-MI patients, n = 33) from a prospective follow-up study enrolling patients with acute chest pain were matched for age and plasma HDL cholesterol. The in vitro capacity of HDL to (1) mediate cholesterol efflux from macrophage foam cells, (2) prevent low-density lipoprotein oxidation, and (3) inhibit TNF-α-induced vascular adhesion molecule-1 expression in endothelial cells was determined. RESULTS: STEMI-HDL displayed reduced cholesterol efflux (P < .001) and anti-inflammatory functionality (P = .001), whereas the antioxidative properties were unaltered. Cholesterol efflux correlated with the anti-inflammatory HDL activity (P < .001). Not C-reactive protein levels, a marker of systemic inflammation, but specifically plasma myeloperoxidase levels were independently associated with impaired HDL function (efflux: P = .022; anti-inflammation: P < .001). Subjects in the higher risk quartile of efflux (odds ratio [OR], 5.66; 95% confidence interval [CI], 1.26-25.00; P = .024) as well as anti-inflammatory functionality of HDL (OR, 5.53; 95% CI, 1.83-16.73; P = .002) had a higher OR for MI vs those in the three lower risk quartiles combined. CONCLUSION: Independent of plasma HDL cholesterol levels, 2 of 3 antiatherogenic HDL functionalities tested were significantly impaired in STEMI patients, namely cholesterol efflux and anti-inflammatory properties. Increased myeloperoxidase levels might represent a major contributing mechanism for decreased HDL functionality in MI patients. Copyright Â
BACKGROUND: High-density lipoproteins (HDLs) protect against the development of atherosclerotic cardiovascular disease. HDL function represents an emerging concept in cardiovascular research. OBJECTIVE: This study investigated the association between HDL functionality and acute myocardial infarction (MI) independent of HDL-cholesterol plasma levels. METHODS:Participants (non-ST-segment elevation MI, non-STEMI, n = 41; STEMI, n = 37; non-MI patients, n = 33) from a prospective follow-up study enrolling patients with acute chest pain were matched for age and plasma HDL cholesterol. The in vitro capacity of HDL to (1) mediate cholesterol efflux from macrophage foam cells, (2) prevent low-density lipoprotein oxidation, and (3) inhibit TNF-α-induced vascular adhesion molecule-1 expression in endothelial cells was determined. RESULTS: STEMI-HDL displayed reduced cholesterol efflux (P < .001) and anti-inflammatory functionality (P = .001), whereas the antioxidative properties were unaltered. Cholesterol efflux correlated with the anti-inflammatory HDL activity (P < .001). Not C-reactive protein levels, a marker of systemic inflammation, but specifically plasma myeloperoxidase levels were independently associated with impaired HDL function (efflux: P = .022; anti-inflammation: P < .001). Subjects in the higher risk quartile of efflux (odds ratio [OR], 5.66; 95% confidence interval [CI], 1.26-25.00; P = .024) as well as anti-inflammatory functionality of HDL (OR, 5.53; 95% CI, 1.83-16.73; P = .002) had a higher OR for MI vs those in the three lower risk quartiles combined. CONCLUSION: Independent of plasma HDL cholesterol levels, 2 of 3 antiatherogenic HDL functionalities tested were significantly impaired in STEMI patients, namely cholesterol efflux and anti-inflammatory properties. Increased myeloperoxidase levels might represent a major contributing mechanism for decreased HDL functionality in MI patients. Copyright Â
Authors: Mithila Vaidya; Julian A Jentsch; Susann Peters; Petra Keul; Sarah Weske; Markus H Gräler; Emil Mladenov; George Iliakis; Gerd Heusch; Bodo Levkau Journal: J Lipid Res Date: 2019-01-17 Impact factor: 5.922
Authors: C Charles-Schoeman; G B Gugiu; H Ge; A Shahbazian; Y Y Lee; X Wang; D E Furst; V K Ranganath; M Maldonado; Terry Lee; S T Reddy Journal: Atherosclerosis Date: 2018-04-17 Impact factor: 6.847
Authors: Negar Sarmadi; Hossein Poustchi; Fatemeh Ali Yari; Amir Reza Radmard; Sara Karami; Abbas Pakdel; Parisa Shabani; Ali Khaleghian Journal: PLoS One Date: 2022-04-12 Impact factor: 3.240
Authors: Trynke van der Boom; Congzhuo Jia; Joop D Lefrandt; Margery A Connelly; Thera P Links; Uwe J F Tietge; Robin P F Dullaart Journal: J Clin Endocrinol Metab Date: 2020-09-01 Impact factor: 5.958
Authors: Sanam Ebtehaj; Eke G Gruppen; Mojtaba Parvizi; Uwe J F Tietge; Robin P F Dullaart Journal: Cardiovasc Diabetol Date: 2017-10-12 Impact factor: 9.951
Authors: Bo Zheng; Danielle Duffy; Pierluigi Tricoci; Helen Kastrissios; Marc Pfister; Samuel D Wright; Andreas Gille; Michael A Tortorici Journal: Br J Clin Pharmacol Date: 2020-12-23 Impact factor: 4.335